Replies to post #770543 on NorthWest Biotherapeutics Inc (NWBO)

[Doc logic]

iclight,

You might want to check when the L Phase 3 started and when the Medicenna trial started. FDA had their chance to insist on patient level data before trial start when they insisted on the crossover to a potentially active treatment which they knew could interfere with interpretation of treatment activity and trial results. Sure, FDA’s decision was the right thing to do for the patients but now their interference with the trial design and the screening halt, which led to 17 SOC/placebo patients being kept out while all treatment arm patients were enrolled, needs to be redemptive for the trial, the company and for future trials that will consider patients enrolled into SOC without hope for a better outcome as unethical when comparators exist that can be utilized instead. One of those comparators may end up looking a lot like what NWBO did in their L Phase 3 trial if my hunch is correct; ). Best wishes.

[iwasadiver]

You might want to email Dr Wen at Harvard and ask him why he refused to share patient level data from his GBM comparator trial with NWBO when they kindly asked. He lied flat out to me when I asked him. Blatantly. Maybe you know some of these dirty people who’d wish to throw any and every road block at DCVax because it’ll ruin the funding gravy train that allows them to lead the cushy lives they do while pretending to be Academic heroes. Then you can explain to everyone here how the SAP found an answer to being denied patient level data which Dr Bosch eloquently described in his defense of their methodology. You can pick at the little chip of paint you guys have left to pick at all you want, we all know you’re going to push until the last moment when you have to cover the mistake you’ve collectively made. Tsk tsk tsk